Skip to main content

Table 2 Antiviral activity IC50 of BFFI in PBMC assays

From: Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

HIV Virus Tropism BFFI* CCR5mAb* T-2635*
NLBal R5 0.13 ± 0.06 0.23 ± 0.09 0.58 ± 0.40
JRCSF R5 0.60 ± 0.13 1.16 ± 0.45 0.29 ± 0.10
YU2.c R5 0.07 ± 0.016 0.24 ± 0.09 0.26 ± 0.12
92US715 R5 0.34 ± 0.19 0.96 ± 0.39 0.55 ± 0.30
CC1/85 R5 0.67 ± 0.36 1.12 ± 0.34 1.41 ± 0.31
Mean R5 0.36 ± 0.27 0.62 ± 0.47 0.74 ± 0.47
p-value vs. BFFI   0.0800 0.0410
NL4-3 X4 >100 >100 0.70 ± 0.31
89.6 R5X4 >100 >100 0.91 ± 0.12
  1. * Results are IC50 ± SD (nM) from 3 or more independent experiments.
  2. The log10 values of the IC50 for all three drugs and R5 virus isolates were compared using a two-way ANOVA model including terms of drug and virus followed by post-hoc comparison using Fisher's LSD test